Supernus Pharmaceuticals, Inc. EPS (Earnings per Share) 2010–2025
Supernus Pharmaceuticals, Inc. reported $-0.68 of earnings per share for fiscal 2025. That was 151.5% lower than fiscal 2024. Compared with fiscal 2020, the change was -128.8%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $-0.68 | -151.5% |
| FY 2024 | $1.32 | +6500.0% |
| FY 2023 | $0.02 | -98.1% |
| FY 2022 | $1.04 | +6.1% |
| FY 2021 | $0.98 | -58.5% |
| FY 2020 | $2.36 | +12.4% |
| FY 2019 | $2.10 | +2.4% |
| FY 2018 | $2.05 | +89.8% |
| FY 2017 | $1.08 | -38.6% |
| FY 2016 | $1.76 | +528.6% |
| FY 2015 | $0.28 | +207.7% |
| FY 2014 | $-0.26 | +91.0% |
| FY 2013 | $-2.90 | -6.6% |
| FY 2012 | $-2.72 | — |
| FY 2011 | $0.00 | — |
| FY 2010 | $0.00 | — |
Source: Supernus Pharmaceuticals, Inc. SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open SUPN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Supernus Pharmaceuticals, Inc. reported $-0.68 of earnings per share for fiscal 2025. That was 151.5% lower than fiscal 2024. Compared with fiscal 2020, the change was -128.8%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Supernus Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSupernus Pharmaceuticals, Inc. — frequently asked questions
What is Supernus Pharmaceuticals, Inc.'s earnings per share?
Supernus Pharmaceuticals, Inc. (SUPN) reported earnings per share of $-0.68 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Supernus Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.